These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 7295089

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical implications of uremic middle molecules in regular hemodialysis patients.
    Asaba H, Alvestrand A, Fürst P, Bergström J.
    Clin Nephrol; 1983 Apr; 19(4):179-87. PubMed ID: 6851254
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Uremic middle molecules in non-dialyzed azotemic patients: relation to symptoms and clinical biochemistries.
    Asaba H, Alvestrand A, Bergström J, Fürst P, Yahiel V.
    Clin Nephrol; 1982 Feb; 17(2):90-5. PubMed ID: 7067171
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Renal handling of middle molecules in uremic patients and in the isolated rat kidney.
    Lustenberger N, Schindhelm K, Nordmeyer C, Schurek HJ, Stolte H.
    Artif Organs; 1981 Feb; 4 Suppl():110-4. PubMed ID: 7295076
    [Abstract] [Full Text] [Related]

  • 10. [Depurative efficiency of intermediate and large molecules with different hemodialysis modalities].
    Maduell F.
    Nefrologia; 2005 Feb; 25 Suppl 2():15-8. PubMed ID: 16050396
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dialysis therapy: 'think differently'.
    Perrone B.
    Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v1-2. PubMed ID: 17586840
    [No Abstract] [Full Text] [Related]

  • 15. [The anticoagulant activity of the plasma ultrafiltrate as a possible criterion of uremic poisoning].
    Sukhanov VA, Chuzhinov SV, Koriakov IO, Zlokazov VB.
    Ter Arkh; 1991 Jul; 63(6):68-71. PubMed ID: 1948752
    [No Abstract] [Full Text] [Related]

  • 16. [Effect of chromatographic fractions of blood ultrafiltrates of patients with chronic uremia on the fibrinolytic activity]].
    Popławski A, Myśliwiec M, Soszka J.
    Pol Tyg Lek; 1991 Jul; 45(40-41):810-3. PubMed ID: 2096374
    [Abstract] [Full Text] [Related]

  • 17. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
    Dirican M, Akca R, Sarandol E, Dilek K.
    J Nephrol; 2004 Jul; 17(6):813-8. PubMed ID: 15593056
    [Abstract] [Full Text] [Related]

  • 18. Skin bleeding time for the evaluation of uremic platelet dysfunction and effect of dialysis.
    Soyoral YU, Demir C, Begenik H, Esen R, Kucukoglu ME, Aldemir MN, Demirkiran D, Erkoc R.
    Clin Appl Thromb Hemost; 2012 Jul; 18(2):185-8. PubMed ID: 22327827
    [Abstract] [Full Text] [Related]

  • 19. Uremic middle molecules: separation and quantitation.
    Chapman GV, Farrell PC.
    Artif Organs; 1981 Jul; 4 Suppl():160-5. PubMed ID: 7295084
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.